Use of Danshensu, Notoginsenoside R1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9101640
APP PUB NO 20120295858A1
SERIAL NO

13505051

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TASLY PHARMACEUTICAL GROUP CO LTDTIANJIN 300410

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Guo, Jun Tianjin, CN 117 350
Han, Jingyan Tianjin, CN 3 1
Liu, Yuying Tianjin, CN 15 88
Sun, Kai Tianjin, CN 143 634
Wang, Mingxia Tianjin, CN 20 84
Yang, Jiying Tianjin, CN 4 1
Zhang, Yu Tianjin, CN 1971 9206

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 11, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00